(NASDAQ: NPCE) Neuropace's forecast annual revenue growth rate of 18.65% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 9.71%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.07%.
Neuropace's revenue in 2026 is $94,864,000.On average, 10 Wall Street analysts forecast NPCE's revenue for 2026 to be $3,347,427,267, with the lowest NPCE revenue forecast at $3,158,072,799, and the highest NPCE revenue forecast at $3,511,301,318. On average, 8 Wall Street analysts forecast NPCE's revenue for 2027 to be $4,228,416,831, with the lowest NPCE revenue forecast at $3,913,658,745, and the highest NPCE revenue forecast at $4,530,517,979.
In 2028, NPCE is forecast to generate $5,370,872,108 in revenue, with the lowest revenue forecast at $5,160,367,229 and the highest revenue forecast at $5,528,750,767.